Intrinsic value of Allscripts Healthcare Solutions - MDRX

Previous Close

$13.38

  Intrinsic Value

$32.21

stock screener

  Rating & Target

str. buy

+141%

Previous close

$13.38

 
Intrinsic value

$32.21

 
Up/down potential

+141%

 
Rating

str. buy

We calculate the intrinsic value of MDRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  23.30
  21.47
  19.82
  18.34
  17.01
  15.81
  14.73
  13.75
  12.88
  12.09
  11.38
  10.74
  10.17
  9.65
  9.19
  8.77
  8.39
  8.05
  7.75
  7.47
  7.22
  7.00
  6.80
  6.62
  6.46
  6.31
  6.18
  6.06
  5.96
  5.86
Revenue, $m
  2,227
  2,705
  3,242
  3,836
  4,489
  5,198
  5,964
  6,784
  7,657
  8,583
  9,560
  10,587
  11,663
  12,789
  13,964
  15,188
  16,463
  17,788
  19,166
  20,599
  22,087
  23,633
  25,241
  26,912
  28,651
  30,460
  32,343
  34,304
  36,348
  38,479
Variable operating expenses, $m
  2,069
  2,448
  2,873
  3,343
  3,860
  4,422
  5,028
  5,678
  6,369
  7,103
  7,571
  8,384
  9,237
  10,128
  11,058
  12,028
  13,037
  14,087
  15,178
  16,313
  17,491
  18,716
  19,989
  21,313
  22,689
  24,122
  25,613
  27,166
  28,785
  30,472
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,069
  2,448
  2,873
  3,343
  3,860
  4,422
  5,028
  5,678
  6,369
  7,103
  7,571
  8,384
  9,237
  10,128
  11,058
  12,028
  13,037
  14,087
  15,178
  16,313
  17,491
  18,716
  19,989
  21,313
  22,689
  24,122
  25,613
  27,166
  28,785
  30,472
Operating income, $m
  158
  258
  369
  493
  629
  776
  935
  1,106
  1,288
  1,480
  1,989
  2,203
  2,427
  2,661
  2,906
  3,160
  3,425
  3,701
  3,988
  4,286
  4,596
  4,917
  5,252
  5,600
  5,961
  6,338
  6,730
  7,138
  7,563
  8,006
EBITDA, $m
  605
  735
  880
  1,042
  1,219
  1,411
  1,619
  1,842
  2,079
  2,330
  2,596
  2,875
  3,167
  3,473
  3,792
  4,124
  4,470
  4,830
  5,204
  5,593
  5,997
  6,417
  6,853
  7,307
  7,779
  8,270
  8,782
  9,314
  9,869
  10,448
Interest expense (income), $m
  42
  95
  138
  187
  243
  304
  372
  445
  524
  609
  699
  795
  895
  1,001
  1,113
  1,229
  1,350
  1,477
  1,608
  1,745
  1,888
  2,035
  2,189
  2,349
  2,515
  2,688
  2,867
  3,054
  3,248
  3,451
  3,662
Earnings before tax, $m
  63
  119
  182
  250
  324
  405
  491
  582
  679
  782
  1,195
  1,307
  1,425
  1,548
  1,677
  1,810
  1,949
  2,093
  2,243
  2,398
  2,560
  2,728
  2,903
  3,085
  3,274
  3,471
  3,676
  3,889
  4,112
  4,344
Tax expense, $m
  17
  32
  49
  67
  88
  109
  132
  157
  183
  211
  323
  353
  385
  418
  453
  489
  526
  565
  606
  648
  691
  737
  784
  833
  884
  937
  992
  1,050
  1,110
  1,173
Net income, $m
  46
  87
  133
  182
  237
  295
  358
  425
  496
  571
  872
  954
  1,041
  1,130
  1,224
  1,321
  1,423
  1,528
  1,637
  1,751
  1,869
  1,992
  2,119
  2,252
  2,390
  2,534
  2,683
  2,839
  3,002
  3,171

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  5,216
  6,336
  7,592
  8,984
  10,512
  12,174
  13,966
  15,887
  17,933
  20,101
  22,389
  24,794
  27,315
  29,951
  32,703
  35,570
  38,555
  41,659
  44,886
  48,240
  51,725
  55,347
  59,112
  63,026
  67,098
  71,334
  75,744
  80,338
  85,124
  90,114
Adjusted assets (=assets-cash), $m
  5,216
  6,336
  7,592
  8,984
  10,512
  12,174
  13,966
  15,887
  17,933
  20,101
  22,389
  24,794
  27,315
  29,951
  32,703
  35,570
  38,555
  41,659
  44,886
  48,240
  51,725
  55,347
  59,112
  63,026
  67,098
  71,334
  75,744
  80,338
  85,124
  90,114
Revenue / Adjusted assets
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
Average production assets, $m
  2,007
  2,438
  2,921
  3,456
  4,044
  4,684
  5,373
  6,112
  6,899
  7,733
  8,613
  9,539
  10,509
  11,523
  12,582
  13,685
  14,833
  16,027
  17,269
  18,559
  19,900
  21,294
  22,742
  24,248
  25,814
  27,444
  29,141
  30,908
  32,749
  34,669
Working capital, $m
  -180
  -219
  -263
  -311
  -364
  -421
  -483
  -549
  -620
  -695
  -774
  -858
  -945
  -1,036
  -1,131
  -1,230
  -1,333
  -1,441
  -1,552
  -1,668
  -1,789
  -1,914
  -2,045
  -2,180
  -2,321
  -2,467
  -2,620
  -2,779
  -2,944
  -3,117
Total debt, $m
  2,302
  3,125
  4,048
  5,071
  6,194
  7,416
  8,733
  10,145
  11,649
  13,242
  14,924
  16,691
  18,544
  20,482
  22,504
  24,612
  26,806
  29,087
  31,459
  33,925
  36,486
  39,148
  41,915
  44,793
  47,785
  50,899
  54,140
  57,516
  61,034
  64,702
Total liabilities, $m
  3,834
  4,657
  5,580
  6,603
  7,726
  8,948
  10,265
  11,677
  13,181
  14,774
  16,456
  18,223
  20,076
  22,014
  24,036
  26,144
  28,338
  30,619
  32,991
  35,456
  38,018
  40,680
  43,447
  46,324
  49,317
  52,431
  55,672
  59,048
  62,566
  66,234
Total equity, $m
  1,382
  1,679
  2,012
  2,381
  2,786
  3,226
  3,701
  4,210
  4,752
  5,327
  5,933
  6,570
  7,238
  7,937
  8,666
  9,426
  10,217
  11,040
  11,895
  12,784
  13,707
  14,667
  15,665
  16,702
  17,781
  18,904
  20,072
  21,289
  22,558
  23,880
Total liabilities and equity, $m
  5,216
  6,336
  7,592
  8,984
  10,512
  12,174
  13,966
  15,887
  17,933
  20,101
  22,389
  24,793
  27,314
  29,951
  32,702
  35,570
  38,555
  41,659
  44,886
  48,240
  51,725
  55,347
  59,112
  63,026
  67,098
  71,335
  75,744
  80,337
  85,124
  90,114
Debt-to-equity ratio
  1.670
  1.860
  2.010
  2.130
  2.220
  2.300
  2.360
  2.410
  2.450
  2.490
  2.520
  2.540
  2.560
  2.580
  2.600
  2.610
  2.620
  2.630
  2.640
  2.650
  2.660
  2.670
  2.680
  2.680
  2.690
  2.690
  2.700
  2.700
  2.710
  2.710
Adjusted equity ratio
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  46
  87
  133
  182
  237
  295
  358
  425
  496
  571
  872
  954
  1,041
  1,130
  1,224
  1,321
  1,423
  1,528
  1,637
  1,751
  1,869
  1,992
  2,119
  2,252
  2,390
  2,534
  2,683
  2,839
  3,002
  3,171
Depreciation, amort., depletion, $m
  447
  477
  511
  549
  590
  635
  684
  736
  791
  850
  607
  672
  740
  811
  886
  964
  1,045
  1,129
  1,216
  1,307
  1,401
  1,500
  1,602
  1,708
  1,818
  1,933
  2,052
  2,177
  2,306
  2,441
Funds from operations, $m
  493
  564
  644
  731
  827
  931
  1,042
  1,161
  1,287
  1,421
  1,479
  1,626
  1,781
  1,942
  2,110
  2,285
  2,467
  2,657
  2,853
  3,058
  3,270
  3,491
  3,721
  3,959
  4,208
  4,466
  4,735
  5,016
  5,308
  5,613
Change in working capital, $m
  -34
  -39
  -43
  -48
  -53
  -57
  -62
  -66
  -71
  -75
  -79
  -83
  -87
  -91
  -95
  -99
  -103
  -107
  -112
  -116
  -121
  -125
  -130
  -135
  -141
  -147
  -153
  -159
  -166
  -173
Cash from operations, $m
  527
  603
  687
  779
  880
  988
  1,104
  1,227
  1,358
  1,496
  1,558
  1,709
  1,868
  2,033
  2,205
  2,384
  2,570
  2,764
  2,965
  3,174
  3,391
  3,616
  3,851
  4,095
  4,349
  4,613
  4,888
  5,175
  5,474
  5,785
Maintenance CAPEX, $m
  -115
  -141
  -172
  -206
  -243
  -285
  -330
  -378
  -430
  -486
  -545
  -607
  -672
  -740
  -811
  -886
  -964
  -1,045
  -1,129
  -1,216
  -1,307
  -1,401
  -1,500
  -1,602
  -1,708
  -1,818
  -1,933
  -2,052
  -2,177
  -2,306
New CAPEX, $m
  -379
  -431
  -483
  -536
  -588
  -639
  -690
  -739
  -787
  -834
  -880
  -925
  -970
  -1,014
  -1,059
  -1,103
  -1,148
  -1,194
  -1,242
  -1,290
  -1,341
  -1,393
  -1,448
  -1,506
  -1,566
  -1,630
  -1,697
  -1,767
  -1,841
  -1,920
Cash from investing activities, $m
  -494
  -572
  -655
  -742
  -831
  -924
  -1,020
  -1,117
  -1,217
  -1,320
  -1,425
  -1,532
  -1,642
  -1,754
  -1,870
  -1,989
  -2,112
  -2,239
  -2,371
  -2,506
  -2,648
  -2,794
  -2,948
  -3,108
  -3,274
  -3,448
  -3,630
  -3,819
  -4,018
  -4,226
Free cash flow, $m
  34
  31
  32
  38
  49
  64
  84
  110
  140
  176
  133
  177
  226
  279
  335
  395
  458
  525
  595
  667
  743
  822
  903
  987
  1,075
  1,165
  1,259
  1,355
  1,456
  1,559
Issuance/(repayment) of debt, $m
  724
  823
  923
  1,023
  1,123
  1,221
  1,318
  1,412
  1,504
  1,594
  1,681
  1,768
  1,853
  1,938
  2,022
  2,107
  2,194
  2,282
  2,372
  2,465
  2,562
  2,662
  2,767
  2,877
  2,992
  3,114
  3,241
  3,376
  3,518
  3,668
Issuance/(repurchase) of shares, $m
  215
  210
  200
  187
  168
  145
  117
  84
  46
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  939
  1,033
  1,123
  1,210
  1,291
  1,366
  1,435
  1,496
  1,550
  1,598
  1,681
  1,768
  1,853
  1,938
  2,022
  2,107
  2,194
  2,282
  2,372
  2,465
  2,562
  2,662
  2,767
  2,877
  2,992
  3,114
  3,241
  3,376
  3,518
  3,668
Total cash flow (excl. dividends), $m
  973
  1,064
  1,156
  1,248
  1,340
  1,430
  1,519
  1,606
  1,690
  1,773
  1,814
  1,945
  2,079
  2,216
  2,357
  2,502
  2,652
  2,807
  2,967
  3,132
  3,305
  3,484
  3,670
  3,864
  4,067
  4,279
  4,500
  4,731
  4,973
  5,227
Retained Cash Flow (-), $m
  -261
  -297
  -333
  -369
  -405
  -440
  -475
  -509
  -542
  -575
  -606
  -637
  -668
  -699
  -729
  -760
  -791
  -823
  -855
  -889
  -924
  -960
  -998
  -1,037
  -1,079
  -1,123
  -1,169
  -1,217
  -1,268
  -1,322
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  712
  767
  823
  879
  935
  990
  1,044
  1,097
  1,148
  1,199
  1,208
  1,308
  1,411
  1,518
  1,628
  1,743
  1,861
  1,984
  2,111
  2,244
  2,381
  2,524
  2,672
  2,827
  2,988
  3,156
  3,331
  3,514
  3,705
  3,905
Discount rate, %
  7.90
  8.30
  8.71
  9.15
  9.60
  10.08
  10.59
  11.12
  11.67
  12.26
  12.87
  13.51
  14.19
  14.90
  15.64
  16.42
  17.24
  18.11
  19.01
  19.96
  20.96
  22.01
  23.11
  24.27
  25.48
  26.75
  28.09
  29.49
  30.97
  32.52
PV of cash for distribution, $m
  660
  654
  640
  619
  591
  556
  516
  472
  425
  377
  319
  286
  251
  217
  184
  153
  125
  99
  77
  59
  44
  32
  22
  15
  10
  7
  4
  3
  1
  1
Current shareholders' claim on cash, %
  91.6
  85.4
  80.7
  77.3
  74.8
  72.9
  71.7
  70.9
  70.6
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5
  70.5

Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.

FINANCIAL RATIOS  of  Allscripts Healthcare Solutions (MDRX)

Valuation Ratios
P/E Ratio 805.1
Price to Sales 1.6
Price to Book 2
Price to Tangible Book
Price to Cash Flow 9
Price to Free Cash Flow 18.4
Growth Rates
Sales Growth Rate 11.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 102.9%
Cap. Spend. - 3 Yr. Gr. Rate 3.5%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 105.8%
Total Debt to Equity 108%
Interest Coverage 1
Management Effectiveness
Return On Assets -0.2%
Ret/ On Assets - 3 Yr. Avg. -1.2%
Return On Total Capital 0.1%
Ret/ On T. Cap. - 3 Yr. Avg. -1.2%
Return On Equity 0.2%
Return On Equity - 3 Yr. Avg. -1.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 43.3%
Gross Margin - 3 Yr. Avg. 41.6%
EBITDA Margin 12.8%
EBITDA Margin - 3 Yr. Avg. 11.5%
Operating Margin 3.9%
Oper. Margin - 3 Yr. Avg. 1.1%
Pre-Tax Margin -1%
Pre-Tax Margin - 3 Yr. Avg. -1.9%
Net Profit Margin 0.2%
Net Profit Margin - 3 Yr. Avg. -1.6%
Effective Tax Rate 120%
Eff/ Tax Rate - 3 Yr. Avg. 141%
Payout Ratio 0%

MDRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDRX stock intrinsic value calculation we used $1806.342 million for the last fiscal year's total revenue generated by Allscripts Healthcare Solutions. The default revenue input number comes from 0001 income statement of Allscripts Healthcare Solutions. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDRX stock valuation model: a) initial revenue growth rate of 23.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.9%, whose default value for MDRX is calculated based on our internal credit rating of Allscripts Healthcare Solutions, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Allscripts Healthcare Solutions.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDRX stock the variable cost ratio is equal to 96.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6% for Allscripts Healthcare Solutions.

Corporate tax rate of 27% is the nominal tax rate for Allscripts Healthcare Solutions. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDRX are equal to 90.1%.

Life of production assets of 14.2 years is the average useful life of capital assets used in Allscripts Healthcare Solutions operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDRX is equal to -8.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1120.882 million for Allscripts Healthcare Solutions - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 174.61 million for Allscripts Healthcare Solutions is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Allscripts Healthcare Solutions at the current share price and the inputted number of shares is $2.3 billion.

RELATED COMPANIES Price Int.Val. Rating
CERN Cerner 62.12 29.77  str.sell
QSII Quality System 22.35 7.94  str.sell
CPSI Computer Progr 26.43 17.38  sell
UNH UnitedHealth G 259.61 561.84  str.buy
MTBC Medical Transc 5.06 6.39  buy
NH NantHealth 1.42 0.02  str.sell
MMM 3M 198.23 232.48  hold
MCK McKesson 130.79 340.66  str.buy
ATHN athenahealth 126.61 54.38  str.sell

COMPANY NEWS

▶ EPSi announces partnership with Ilerasoft   [Sep-17-18 04:01PM  GlobeNewswire]
▶ Allscripts will sell 51 percent stake in Netsmart   [Aug-07-18 03:34PM  American City Business Journals]
▶ AllScripts: 2Q Earnings Snapshot   [04:13PM  Associated Press]
▶ Allscripts closes acquisition of HealthGrid   [May-21-18 08:01AM  GlobeNewswire]
▶ AllScripts: 1Q Earnings Snapshot   [May-03-18 04:50PM  Associated Press]
▶ MedStar study: Electronic health records might be leading to patient harm   [Mar-29-18 03:01PM  American City Business Journals]
▶ Allscripts launches industrys first machine learning EHR   [Mar-06-18 08:01AM  GlobeNewswire]
▶ Allscripts, Lyft partner on health care transportation   [Mar-05-18 08:43AM  MarketWatch]
▶ [$$] Patients Missing Doctor Visits Get Helping Hand   [07:30AM  The Wall Street Journal]
▶ AllScripts meets 4Q profit forecasts   [04:27PM  Associated Press]
▶ Allscripts Names Dennis Olis Chief Financial Officer   [Jan-31-18 04:01PM  GlobeNewswire]
▶ Allscripts to acquire Practice Fusion business   [Jan-08-18 08:01AM  GlobeNewswire]
▶ Allscripts to attend upcoming investor events   [Dec-04-17 04:01PM  GlobeNewswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.